Team:UCL/Background

From 2013.igem.org

(Difference between revisions)
Line 79: Line 79:
<div class="col_links">
<div class="col_links">
-
<p class="minor_title">Links</p>
+
<p class="minor_title">Links</p>
<p class="citation_text"><a href="http://www.alzheimers.org.uk/">Alzheimer’s Society</a></p>
<p class="citation_text"><a href="http://www.alzheimers.org.uk/">Alzheimer’s Society</a></p>
<p class="citation_text"><a href="http://www.alz.co.uk/">Alzheimer’s Disease International</a></p>
<p class="citation_text"><a href="http://www.alz.co.uk/">Alzheimer’s Disease International</a></p>
Line 105: Line 105:
<div class="col_links">
<div class="col_links">
-
<p class="citation_text">Links and citations here.</p>
+
<p class="minor_title">Links</p>
 +
<p class="citation_text"><a href="http://www.alzgene.org/ ">Alzheimer’s Genetics</a></p>
 +
<p class="citation_text"><a href="http://www.nature.com/nrn/posters/ad/nrn_ad_posters.pdf">Alzheimer’s infographic</a></p>
 +
<p class="citation_text"><a href="http://www.nature.com/nrd/journal/v10/n9/full/nrd3505.html">The Amyloid Hypothesis</a></p>
 +
<p class="citation_text"><a href="http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=147">Current Drug Treatments</a></p>
</div>
</div>
Line 129: Line 133:
<div class="col_links">
<div class="col_links">
-
<p class="citation_text">Links and citations here.</p>
+
<p class="minor_title">Links</p>
 +
<p class="citation_text"><a href="http://www.nature.com/scibx/journal/v3/n14/full/scibx.2010.423.html">Microglia in AD</a></p>
 +
<p class="citation_text"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20182045">Neuroinflammation in AD</a></p>
 +
<p class="citation_text"><a href="http://www.bionity.com/en/encyclopedia/Microglia.html">Nature of Microglia</a></p>
 +
<p class="citation_text"><a href="http://www.sciencemag.org/content/330/6005/783.full">The Changing Face of Microglia</a></p>
</div>
</div>

Revision as of 16:44, 14 August 2013

BACKGROUND INFO

Alzheimer's Disease

Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the brain, creating synthetic biological systems capable of rectifying abnormalities in the brain on a cellular and macromolecular level.

Such novel application of synthetic biology could offer new ways to treat brain diseases, such as our target, Alzheimer’s disease, for which most modern pharmaceutical treatment is purely symptomatic.